# Accele Venture Partners

> Accele Venture Partners is a VC fund backing Health Care and Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Oklahoma City, United States
- Total investments: 7
- Last investment: Feb 2016
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/briggsly
- Website: http://accelebio.com/

Accele Venture Partners is a VC fund in Oklahoma City focused on Health Care and Biotechnology. Accele Venture Partners is the special purposes venture fund of life sciences accelerator Accele Biopharma, Inc

## Contacts

5 contacts available for Accele Venture Partners. Shizune tracks 1 team members at Accele Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/accele-venture-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 29% |
| Biotechnology | 2 | 29% |
| Machine Learning | 2 | 29% |
| Information Technology | 2 | 29% |
| EdTech | 1 | 14% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 2 | 29% |
| Seed | 1 | 14% |
| Series A | 1 | 14% |
| Series F | 1 | 14% |
| Debt Financing | 1 | 14% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 71% |
| India | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Clayton I. Duncan | CEO | 0 | https://shizune.co/investors/profile/clayton-i-duncan |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SigTuple | SigTuple's vision is to revolutionise the global medical diagnostic space through data driven intelligence. They aim to create a data driven, machine learned, cloud based solution for detection of anomalies and trends in medical data, which improves the accuracy and efficiency of disease diagnosis. |  | Seed | Feb 22, 2016 |  |
| Knewton | Knewton's mission is to personalize learning for the world. Teachers, schools, and education companies around the world use Knewton to power digital course materials that dynamically adapt to each student’s unique needs. Knewton provides students with tailored recommendations for exactly what to study, teachers with analytics to bettersupport each student, and publishers with content insights to develop more effective digital products.Knewton was founded in 2008 and has offices in New York City, London, Tokyo, Singapore, and Dubai. Knewton has been recognized globally as a “Technology Pioneer” (World Economic Forum in Davos) and several times as one of the top 10 most innovative companies in education (Fast Company). | $10M | Series F | Feb 02, 2016 |  |
| Synereca Pharmaceuticals | Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. Its portfolio includes prototypic RecA inhibitors, which target various pathogenic bacteria/E. coli, including those responsible for lung, urinary tract, and skin infections, as well as weaponizable gram-positive andgram-negative pathogens through various bactericidal antibiotics. The company was incorporated in 2009 and is based in Chapel Hill, North Carolina. | $600K |  | Aug 04, 2015 |  |
| Synereca Pharmaceuticals | Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. Its portfolio includes prototypic RecA inhibitors, which target various pathogenic bacteria/E. coli, including those responsible for lung, urinary tract, and skin infections, as well as weaponizable gram-positive andgram-negative pathogens through various bactericidal antibiotics. The company was incorporated in 2009 and is based in Chapel Hill, North Carolina. | $1.4M | Debt Financing | Sep 16, 2014 |  |
| Otologic Pharmaceutics | Otologic Pharmaceutics, Inc. is a company committed to developing treatments for acute hearing loss to reduce the development of permanent hearing disorders.OPI’s lead program HPN1010, an oral medication to treat acute hearing loss, will enter clinical trials in 2014. Initial research focuses on Noise Induced Hearing Loss. We will continue towork to expand the applicability of HPN1010 to treat hearing loss from other causes, such as Cisplatin Induced Hearing loss. | $4.1M | Series A | Apr 03, 2014 |  |
| Quokka Sports | Quokka Sports, Inc. provides sports entertainment services for the global digital world. The company operates through two divisions: Qmedia, a media production division; and Qtech, a live content technology solutions division. QMedia's principal activities include the acquisition and control of digital rights; production of live sports andentertainment content; publishing and production of web content such as website development for live events, content production, and website maintenance; and creative sponsorship campaign development and sales. QTech develops and manages the company's proprietary Live_IP technology and services that focus on delivering real-time and near real-time immersive media content for the internet, broadband, interactive and enhanced TV, and wireless platforms. The Live_IP platform consists of two primary components, a near real-time content viewer and a live content publishing system. These tools offer content producers, a browser-based publishing platform for creating, editing, assembling, and laying out media-rich content into overlapping content layers that aid content producers in the complete production of projects. | $76M | Post-IPO Equity | Sep 18, 2000 |  |
| ROI Direct.com | Founded in June of 1999, ROI Direct offers e-commerce site development and hosting, e-marketing program design and execution, and online customer care solutions tailored to Their clients’ needs. They provide application services, 24x7 systems management, account support, feature upgrades, and shared use of Their multi-million dollar systemsinfrastructure for less than Their clients’ typical costs of a single IT employee. By customizing Their re-usable set of advanced applications, They’re also able to deliver these solutions in a fraction of the time of in-house or competing third-party solutions. | $12.9M |  | Feb 25, 2000 |  |

7 of 7 investments shown.

## Co-investors
- [i2E](https://shizune.co/investors/profile/i2e) — VC Fund, 3 deals together
- [AllegisCyber](https://shizune.co/investors/profile/allegis-capital) — VC Fund, 1 deal together
- [Atomico](https://shizune.co/investors/profile/atomico) — VC Fund, 1 deal together
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund, 1 deal together
- [Crosspoint Venture Partners](https://shizune.co/investors/profile/crosspoint-venture-partners) — VC Fund, 1 deal together
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Accele Venture Partners invest in?

Accele Venture Partners invests primarily in Health Care, Biotechnology and Machine Learning startups, most often at Funding Round and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Accele Venture Partners?

Public channels for Accele Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Accele Venture Partners?

The team at Accele Venture Partners includes Clayton I. Duncan (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co